Previous studies detected MB positivity in ~40% of primary breast tumors, mainly in a mosaic-like pattern in luminal-type, estrogen receptor (ER)-positive cases [10], and in ~53% of prostate cancer tumors, mostly in androgen-receptor positive and poorly differentiated entities [46]. This evidence concerns the gene ESR1 and breast neoplasm.